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Sixteen patients with persistent (n 11) or recurrent (n 5) variceal bleeding after injection
sclerotherapy and balloon tamponade were treated with an intravenous infusion of somatostatin 250/g/
h. Somatostatin infusion successfully controlled the bleeding in 15 of the 16 patients but one rebled after
72 h of treatment. In one patient with poor liver function (Child’s C) bleeding was not controlled by
somatostatin, further injection sclerotherapy or balloon tamponade of the oesophagus. The results of
this study, although uncontrolled and with a small number of patients, suggest that somatostatin is a very
effective treatment for the control of post-injection sclerotherapy variceal bleeding.
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INTRODUCTION
Injection sclerotherapy is successful in controlling acute variceal bleeding in
85-95% of patients1’2. If bleeding persists immediately after completion of the
sclerotherapy or recurs early (within 24 h), haemostasis can be achieved in the
majority of cases by balloon tamponade of the oesophagus. However, tamponade
of the oesophagus is associated with a complication rate of approximately 25%3 and
the risk of perforation or ulceration may be increased after injection sclerotherapy
since the sclerosant renders the mucosa more friable4. Consequently, it has been
recommended that mechanical compression of the oesophagus should not exceed
12 h after sclerotherapy3. Therefore if the patient continues to bleed or rebleeding
occurs early after balloon tamponade instituted to control haemorrhage after
injection sclerotherapy, there is a need for an alternative therapy to achieve
haemostasis. In view of the reported efficacy of somatostatin in the control of acute
variceal bleeding51, we describe our experience with the hormone in controlling
significant bleeding from the varices after failed injection sclerotherapy and balloon
tamponade.
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PATIENTS AND METHODS
Between January 1985 and December 1988, 106 patients presented with acute
variceal haemorrhage which was treated with injection sclerotherapy.
Injection sclerotherapy was always carried out under general anaesthesia using a
William’s overtube. Every attempt was made to inject 2-3ml of ethanolamine
oleate intravariceally. On some occasions however, the sclerosant was accidentally
injected paravariceally. If significant oozing persisted after two 10 min periods of
compression with the overtube, balloon tamponade of the oesophagus was insti-
tuted for 12 h (Minnesota tube, gastric balloon 300 ml air, oesophageal balloon 40
mm Hg).
During the study period 11 patients continued to bleed or experienced early
recurrent variceal haemorrhage (n 5) within 12 h after a period of balloon
tamponade instituted to achieve haemostasis after injection sclerotherapy. In all
these patients, the continued or recurrent variceal bleeding was significant as
defined by either (1). a systemic disturbance (blood pressure less than ]00 mm Hg
and pulse rate greater than 100 beats min) requiring blood transfusion to maintain
the vital signs or (2). the necessity to transfuse two or more units of blood in 24 h to
maintain the haemoglobin levels.
The causes of portal hypertension, grading of hepatic function according to the
criteria of Child11, age, sex, blood transfusion requirements and the duration of
somatostatin therapy are shown in Table 1.
Table 1 Details of patients with persistent or recurrent varieceal haemorrhage after injection scleroth-
erapy
Number of patients (M/F) 16 (11/5)
Age Median (range) 56.5 (39-73)
Child’s grading
A 3
B 5
C 8
AETIOLOGY:
Non-cirrhotic
Extrahepatic block 2
Cirrhosis
Alcoholic 10
Cryptogenic 3
Primary biliary cirrhosis
Blood transfusion requirements (units)
After Injection Sclerotherapy prior to Somatostatin infusion
Median (range) 5 (3-12)
After commencement of somatostatin infusion
Median (range) 3 (2-11)
Period of somatostatin treatment (h)
Mean Median (range) 72 (48-120)
Somatostatin Administration
All 16 patients received a continuous infusion of 250/zg/h somatostatin. Special
precuations were taken to ensure that the somatostatin infusion was not interrupted
even for a short period, e.g. overlapping of the infusion bags. As soon as theRECURRENT VARICEAL BLEEDING 223
infusion was established all patients received a bolus injection of 250/g somatosta-
tin which was repeated daily for the duration of the treatment. If for any reason the
infusion was interrupted, a further bolus dose of 250/g was administered as soon as
it was re-established.
Success of Treatment
Successful control of haemorrhage was defined as the cessation of bleeding as
evidenced by the absence of overt signs or by a stable haematocrit and haemoglobin
levels without need for blood transfusion.
RESULTS
During the study period 33 patients (31%) required balloon tamponade of the
oesophagus immediately after injection sclerotherapy to control persistent oozing
from the varices despite two periods of compression with the overtube. Bleeding
was controlled in 17 patients (19%) by 12 h of balloon tamponade. Since we
consider balloon tamponade of the oesophagus to control persistent oozing from
the varices after injection sclerotherapy an integral part of the procedure, the
overall success rate of injection sclerotherapy was 90/106 (85%).
Bleeding persisted or recurred (within 12 h) from the varices in 16 patients
(15%). A continuous infusion of somatostatin controlled bleeding in 15 of the 16
patients (94%). No further bleeding occurred in 14 patients and 12 were placed on
an elective injection sclerotherapy programme to obliterate their varices (Figure 1).
Two patients died without any recurrent haemorrhage during their period of
hospitalisation, one from hepatic failure and the other from a myocardial infarction
(Figure 1). One patient rebled after 72 h treatment with somatostatin and
underwent a second course of injection sclerotherapy. The bleeding persisted
despite a further period of balloon tamponade and somatostatin infusion. An
emergency oesophageal transection was carried out which controlled the bleeding
and this patient made an uneventful recovery (Figure 1).
Bleeding was not controlled by somatostatin in one patient and persisted despite
concomitant balloon tamponade and further injection sclerotherapy (Figure 1). An
emergency oesophageal transection controlled the bleeding but the patient died 20
days post-operatively from hepatic and renal failure.
DISCUSSION
Injection sclerotherapy is a very effective treatment for controlling bleeding
oesophageal varices, haemorrhage being controlled in approximately 85-90% of
patients1’2. Occasionally bleeding persists after a course of injection sclerotherapy,
either emergency or elective, and it is the policy in our unit to use balloon
tamponade immediately after the procedure if massive oozing continues. However,
balloon tamponade of the oesophagus is not without side-effects, among which
oesophageal perforation and necrosis resulting in ulcer formation are among the
more serious. Furthermore, the risks of these two complications may be increased
after injection sclerotherapy because of the deleterious effects of the sclerosant on224 S.A. JENKINS ETAL.
OUTCOME OF SOMATOSTATIN TREATMENT
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Figure 1 Outcome of patients receiving somatostatin after the failure of injection sclerotherapy and 12 h
balloon tamponade to control bleeding.
the oesophageal mucosa4. Consequently, it has been suggested that the period of
balloon tamponade of the oesophagus be restricted to 12 h to minimise oesophageal
perforation and ulceration and other deleterious side effects3. If bleeding continues
after 12 h of tamponade or recurs early after removal of the tube control of the
haemorrhage can be problematical. Further periods of balloon tamponade of the
oesophagus may control bleeding, but the complication rate may be unacceptably
high. Similarly, a second course of injection sclerotherapy may control the
haemorrhage, but in those patients in which bleeding is not controlled the mortality
approaches ]00% 2. Furthermore, emergency oesophageal transection with abdo-
minal devascularisation is often unrewarding because of the difficulties in mobilis-
ing the oesophagus after previous injection sclerotherapy
11 and the high morbidity
and mortality of emergency surgical intervention to control bleeding in patients
12 17 with poor liver functionRECURRENT VARICEAL BLEEDING 225
The results of the present study clearly indicate that somatostatin infusion is a
very safe and effective treatment for the control of substantial variceal haemorr-
hage after failed injection sclerotherapy followed by 12 h balloon tamponade. Thus
initial control of bleeding was achieved in 15 of the 16 patients without any
undesirable side effects. The patient who rebled after 72 h of treatment with
somatostatin (Child’s B) had moderate liver dysfunction and bleeding was
controlled by oesophageal transection from which she made an uneventful reco-
very. The one patient in which somatostatin failed to control the bleeding had
severe liver dysfunction (Child’s C) with large varices and haemostasis was not
achieved by further injection sclerotherapy and balloon tamponade. Although
bleeding was controlled by emergency oesophageal transection the patient died
post-operatively from progressive hepato-renal failure, the usual outcome, of
emergency surgery in patients with severe hepatic dysfunction. Therefore, overall
somatostatin was effective in controlling post injection sclerotherapy in 87.5% of
the patients.
The precise mechanism whereby somatostatin is effective in controlling variceal
haemorrhage has not been fully established. Somatostatin has been demonstrated
to reduce portal pressure in both experimental animals and in patients with
cirrhosis18-2. However, perhaps more importantly, the hormone has a much greater
effect on collateral and azygous blood flow than on portal pressure2122.
Consequently, a reduction in collateral blood flow, including that through the
varices may be a major factor in controlling hamorrhage. Furthermore, although
erosion of the varices by reflux of gastric content is not thought to contribute to
variceal bleeding per se, the marked inhibitory effect of sandostatin on basal and
stimulated gastric secretion of acid and pepsin
22-24 may present clot dissolution and
hence recurrent haemorrhage.
In summary therefore, somatostatin would appear to be a safe and effective
therapy for the control of variceal bleeding after injection sclerotherapy. Clearly,
however, further randomised controlled trials are necessary to substantiate this
hypothesis. Furthermore, since the risk of rebleeding is greatest in the first 5 days
after variceal haemorrhage23’24, somatostatin or its synthetic analogue somatostatin,
may be a useful routine adjuvant therapy to injection sclerotherapy to reduce the
risk of recurrent haemorrhage. Again, however, further studies are required to
substantiate this hypothesis.
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INVITED COMMENTARY
Injection sclerotherapy is widely accepted as the treatment of choice for acute
variceal bleeding. Control of bleeding is achieved in about ninety per cent ofRECURRENT VARICEAL BLEEDING 227
patients with a mortality of around 20 per cent, half of which is due to liver failure.
Should bleeding recur after the first injection, mose centres are prepared to have a
second attempt at sclerotherapy. The use of tamponade in 31 per cent of patients
undergoing acute sclerotherapy in this series is very high. Tamponade, although
useful, is uncomfortable, risky and temporary. An intravenous injection of 10 mg
of metaclopramide controls post-injection oozing in the majority of patients. When
two injections fail to control bleeding, it is suggested that emergency transection
should be performed since the mortality is high in patients who require three or
more injections1. However the results of emergency transection after failed scler-
otherapy are far from encouraging2. Unfortunately the patients who fail to stop
bleeding are often in Child’s Class C where the mortality for emergency surgery
varies from 70-100 per cent.
In many publications, somatostatin and its longer-acting analogue, octreotide
(Sandostatin), have been shown to be as effective or better than placebo, vasopres-
sin, tamponade and acute sclerotherapy respectively in the early management of
acute variceal bleeding. In this paper the extension of the use of these drugs to the
management of post-iniection bleeding has produced encouraging results. In the
Liverpool series only four patients per annum fall into the category of post injection
bleeders, making a controlled trial impossible. Although only half of their patients
were Child’s Class C patients, the results are encouraging to surgeons reluctant to
undertake operative salvage of these difficult patients. Elsewhere the authors have
shown that somatostatin is effective whether post-injection bleeding is due to
recurrent variceal bleeding, post-injection ulceration or oesophagitis. While wait-
ing for further results from other centres, many of us have been encouraged to
adopt octreotide (Sandostatin) therapy for these post-injection bleeders.
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